MedTrace Logo

Adolescent MenACWY Booster Study

NCT03694405 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2022-03-11

No results posted yet for this study

Summary

This study is to confirm non-inferiority of the three MenACWY vaccines (Menveo, Menactra or Nimenrix) in adolescents, and to identify whether the number of previous doses of MenC influences the response to the MenACWY vaccine.

Conditions

  • Meningococcal Disease, Invasive

Interventions

BIOLOGICAL

MenACWY-CRM

Booster vaccination with MenACWY-CRM

BIOLOGICAL

MenACWY-DT

Booster vaccination with MenACWY-DT

BIOLOGICAL

MenACWY-TT

Booster vaccination with MenACWY-TT

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • University of Calgary

    collaborator OTHER

  • Canadian Center for Vaccinology

    collaborator OTHER

  • Alberta Health services

    collaborator OTHER

  • British Columbia Centre for Disease Control

    collaborator OTHER_GOV

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Dalhousie University

    collaborator OTHER

  • Canadian Immunization Research Network

    lead NETWORK

Principal Investigators

  • Manish Sadarangani, BM BCh DPhil · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-20
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03694405 on ClinicalTrials.gov